Key Points {#FPar1}
==========

Adalimumab has a well-established safety profile across multiple indications.In patients with hidradenitis suppurativa, psoriasis, and non-dermatologic indications, the safety of adalimumab 40-mg every other week and every week dosing regimens was comparable.The current analysis supports and further adds to the known safety profile of adalimumab.

Introduction {#Sec1}
============

Hidradenitis suppurativa (HS) is a chronic painful skin disease characterized by abscesses, nodules, and scarring predominantly in the axillary and groin regions \[[@CR1]\]. Prevalence estimates for HS range from 0.05 to 4% \[[@CR2]--[@CR4]\]. Elevated concentrations of tumor necrosis factor (TNF) have been found in the serum and skin lesions of patients with HS \[[@CR5], [@CR6]\] and psoriasis \[[@CR7], [@CR8]\].

Adalimumab is a fully human, highly specific anti-TNF monoclonal antibody approved for the treatment of moderate to severe HS and chronic plaque psoriasis \[[@CR9], [@CR10]\]. Adalimumab is also indicated by the US FDA and the European Medicines Agency for the treatment of rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, juvenile idiopathic arthritis, psoriatic arthritis, ulcerative colitis, and uveitis \[[@CR9], [@CR10]\].

For patients with HS, the recommended dosage of adalimumab is an initial dose of 160 mg followed by an 80-mg dose 2 weeks later and subsequent 40-mg doses every week (EW) thereafter. For adult patients with psoriasis, the recommended adalimumab dosage is an initial dose of 80 mg, followed by subsequent 40-mg doses every other week (EOW) starting 1 week after the initial dose \[[@CR9]\]. The dosing recommendation for adult plaque psoriasis was updated in the EU in 2015 to state that patients with inadequate response with EOW dosing may benefit from an increase in dosing frequency to 40 mg EW after 16 weeks \[[@CR9], [@CR11]\].

The objective of this analysis was to examine the safety of adalimumab 40 mg EOW and EW in patients with HS or psoriasis during placebo-controlled and extended open-label study periods and to explore complementary data from other indications (Crohn's disease, ulcerative colitis, and rheumatoid arthritis) for which direct comparisons of safety data from EOW and EW dosing in the same study were available.

Methods {#Sec2}
=======

Study Designs {#Sec3}
-------------

### Hidradenitis Suppurativa {#Sec4}

Adalimumab was evaluated for the treatment of HS in a phase II, double-blind, placebo-controlled trial (NCT00918255) \[[@CR12]\] and two phase III, double-blind, placebo-controlled trials (PIONEER I \[NCT01468207\] and II \[NCT01468233\]) \[[@CR13]\]. In the phase II study, patients were randomly assigned 1:1:1 to receive 16 weeks of treatment with placebo, adalimumab 40 mg EOW, or adalimumab 40 mg EW. In the phase III studies, patients with moderate to severe HS received adalimumab 40 mg EW or placebo in period A for 12 weeks. In period B, patients who received adalimumab 40 mg EW in period A were re-randomized to receive adalimumab 40 mg EOW, 40 mg EW, or placebo for 24 weeks; data from these patients directly comparing adalimumab EOW or EW and placebo were included in this analysis (Fig. [1](#Fig1){ref-type="fig"}a).Fig. 1Study designs of **a** the hidradenitis suppurativa phase III, PIONEER I and II studies, **b** the psoriasis phase II, double-blind, placebo-controlled study, and **c** the psoriasis open-label study. *EOW* every other week, *EW* every week, *PASI* Psoriasis Area and Severity Index, *PASI50* ≥ 50% improvement in PASI, *PASI75* ≥ 75% improvement in PASI. ^a^Starting at week 4 following 160 mg at week 0 and 80 mg at week 2. ^b^Patients receiving adalimumab 40 mg EW, initially received adalimumab 80 mg at weeks 0 and 1 and then 40 mg weekly starting at week 2; patients receiving adalimumab 40 mg EOW, initially received adalimumab 80 mg at week 0 (week 13 for those randomized to placebo) and then 40 mg EOW starting 1 week later. ^c^One patient was randomized but withdrew consent and did not receive treatment. ^d^If \< PASI50 (relative to baseline of original study start) at any time from week 24 on. ^e^If ≥ PASI75 (relative to baseline of original study start) at any time after dose escalation. ^f^If \< PASI50 (relative to baseline of original study start) at any time after de-escalating, after which patients remained on adalimumab 40 mg EW

### Psoriasis {#Sec5}

The safety of adalimumab was assessed in a phase II, randomized, double-blind, placebo-controlled trial in adults with moderate to severe chronic plaque psoriasis (NCT00645814) \[[@CR14]\]. In this trial, patients were randomized 1:1:1 to receive placebo, adalimumab 40 mg EOW, or adalimumab 40 mg EW for 12 weeks followed by a 48-week extension phase (Fig. [1](#Fig1){ref-type="fig"}b); only data from the initial 12-week, double-blind placebo-controlled period directly comparing EOW and EW dosing and placebo were included in this analysis.

Patients completing the extension and patients from other phase II/III studies of adalimumab \[[@CR14]--[@CR18]\] were eligible for enrollment in another study (NCT00195676) \[[@CR19]\], in which adults with moderate to severe chronic plaque psoriasis received open-label adalimumab EOW or EW for up to 252 weeks (Fig. [1](#Fig1){ref-type="fig"}c). In this study, patients received adalimumab 40 mg EOW for 24 weeks. From weeks 24 to 252, patients with \< 50% improvement in Psoriasis Area and Severity Index (PASI) score could escalate their dose to adalimumab 40 mg EW. Patients who achieved ≥ 75% improvement in PASI score were de-escalated to adalimumab 40 mg EOW but were eligible to be re-escalated to EW dosing if PASI improvement fell to \< 50%. Patients who re-escalated could not de-escalate their adalimumab dose for the remainder of the study. Data after dose de-escalation to adalimumab 40 mg EOW were not included in this analysis (Fig. [1](#Fig1){ref-type="fig"}c)

### Other Indications {#Sec6}

Three double-blind, placebo-controlled studies, including two in Crohn's disease (NCT00077779 \[[@CR20]\] and NCT00055497 \[[@CR21]\]) and one in rheumatoid arthritis \[[@CR22]\], compared the safety of placebo, adalimumab 40 mg EOW, and adalimumab 40 mg EW; the designs and results of these studies have been reported previously \[[@CR20]--[@CR22]\]. The safety of open-label adalimumab 40 mg EOW versus 40 mg EW was assessed in seven studies, including four in Crohn's disease (NCT00077779 \[[@CR20]\], NCT00055497 \[[@CR21]\]/NCT01070303, NCT00195715 \[[@CR23]\], and NCT00348283 \[[@CR24]\]) and three in ulcerative colitis (NCT00385736 \[[@CR25]\], NCT00408629 \[[@CR26]\], and NCT00573794). Dose escalation to open-label 40-mg EW dosing was performed in patients with sustained non-response to treatment or recurrent disease flare.

Statistical Methods {#Sec7}
-------------------

Adverse events (AEs) are presented as number of events and rate of events per 100 patient-years (E/100 PY). Treatment-emergent AEs were defined as any AE with an onset date on or after first dose of study medication in the study period and up to 70 days after the last dose of study medication.

Patients provided informed consent, and individual study protocols were approved by independent ethics committees or institutional review boards at each site.

Results {#Sec8}
=======

Disposition of the Patients {#Sec9}
---------------------------

For HS, this analysis included 153 patients with data from the phase II study and 300 patients with data from period B of the two phase III HS studies. Baseline demographic characteristics were generally similar between the placebo, EOW, and EW groups, except for a higher percentage of White patients in the EW group in the pooled phase III data (*P* = 0.016 between groups; Table [1](#Tab1){ref-type="table"} \[[@CR27]\]).Table 1Baseline demographic and clinical characteristics of adults with hidradenitis suppurativaCharacteristicPhase II: 16-week placebo-controlled studyPhase III: pooled 24-week placebo-controlled period B^a^PBO (*n* = 51)EOW (*n* = 52)EW (*n* = 51)EW/PBO (*n* = 100)EW/EOW (*n* = 101)EW/EW (*n* = 99)Female36 (70.6)38 (73.1)36 (70.6)56 (56.0)65 (64.4)66 (66.7)Age, years37.8 ± 12.136.1 ± 12.535.1 ± 10.736.5 ± 10.935.9 ± 10.534.8 ± 10.2White37 (72.5)36 (69.2)37 (72.5)81 (81.0)77 (76.2)90 (90.9)Weight, kg96.5 ± 24.899.8 ± 26.895.4 ± 22.995.8 ± 26.192.6 ± 22.292.1 ± 21.2Tobacco user29 (56.9)26 (50.0)30 (58.8)54 (54.0)65 (64.4)59 (59.6)Disease duration, years13.4 ± 10.410.9 ± 9.011.3 ± 9.111.6 ± 9.811.7 ± 8.011.8 ± 8.8Hurley stage^b^ I7 (13.7)9 (17.3)8 (15.7)------ II29 (56.9)28 (53.8)28 (54.9)55 (55.0)52 (51.5)49 (49.5) III15 (29.4)15 (28.8)15 (29.4)45 (45.0)49 (48.5)50 (50.5)Data are presented as*n* (%) or mean ± standard deviation*EOW* every-other-week dosing of adalimumab, *EW* every-week dosing of adalimumab, *PBO* placebo^a^EW/PBO indicates an initial period of EW treatment followed by PBO treatment; EW/EOW indicates an initial period of EW treatment followed by EOW treatment; EW/EW indicates an initial period of EW treatment followed by continued EW treatment^b^Hurley stage disease classification is based on the presence and extent of abscesses and sinus tract formation \[[@CR27]\]

In the phase II psoriasis trial, 52 patients received placebo, 45 adalimumab 40 mg EOW, and 50 adalimumab 40 mg EW. Most patients (140/147 \[95%\]) completed the 12-week double-blind period. In the long-term open-label extension psoriasis study, 1256 patients received EOW dosing between weeks 1 and 24, and 907 patients continued EOW dosing throughout the study; 349 escalated to EW dosing at or after week 24 (Fig. [1](#Fig1){ref-type="fig"}c). Of these 349 patients, 182 continued on EW dosing and 167 de-escalated to EOW dosing, with 83 of these patients re-escalating to EW dosing and 84 continuing with EOW dosing. Exposure was determined based on the time that patients were receiving each dosing regimen. Baseline demographic and disease characteristics were generally similar between the placebo, EOW, and EW groups in the double-blind, placebo-controlled trial and between the open-label EOW and EW populations (Table [2](#Tab2){ref-type="table"}).Table 2Baseline demographic and clinical characteristics of adults with psoriasisCharacteristicPhase II, 12-week placebo-controlled studyOpen-label extension studyPBO (*n* = 52)EOW (*n* = 45)EW (*n* = 50)EOW (*n* = 1256)EW (*n* = 349)Female18 (34.6)13 (28.9)17 (34.0)406 (32.3)134 (38.4)Age, years43.3 ± 13.145.8 ± 11.643.8 ± 13.344.4 ± 12.944.1 ± 11.6White48 (92.3)40 (88.9)45 (90.0)1157 (92.1)325 (93.1)Weight, kg93.8 ± 23.293.3 ± 21.798.5 ± 23.292.3 ± 22.797.7 ± 23.8Tobacco user18 (34.6)10 (22.2)17 (34.0)420 (33.5)118 (33.8)Disease duration, years19.1 ± 9.620.5 ± 13.018.4 ± 11.319 ± 11.618 ± 10.5PGA Moderate28 (53.8)14 (31.1)21 (42.0)618 (52.1)166 (48.3) Severe15 (28.8)25 (55.6)21 (42.0)495 (41.7)155 (45.1) Very severe4 (7.7)4 (8.9)4 (8.0)73 (6.2)23 (6.7)Data are presented as*n* (%) or mean ± standard deviation*EOW* every-other-week dosing of adalimumab, *EW* every-week dosing of adalimumab, *PBO* placebo, *PGA* Physician Global Assessment

Duration of Exposure to Adalimumab Treatment {#Sec10}
--------------------------------------------

In the phase II HS study, exposure to adalimumab was similar across treatment groups. In the phase III HS studies, exposure to adalimumab during period B was similar in the placebo and EOW groups but slightly longer in the EW group (Table [3](#Tab3){ref-type="table"}). In the psoriasis studies, exposure to adalimumab was similar in all treatment groups in the placebo-controlled analyses; during the open-label study, EOW exposure to adalimumab was longer than EW exposure.Table 3Duration of exposure to adalimumab treatment in studies of adalimumab for adults with dermatologic conditionsExposure, daysHSPsoriasisPlacebo-controlled dataPBO^a^ (*n* = 51)EOW^a^ (*n* = 52)EW^a^ (*n* = 51)PBO (*n* = 52)EOW (*n* = 45)EW (*n* = 50)104.0 ± 25.6112.9 ± 2.5107.4 ± 20.182.9 ± 11.982.9 ± 10.881.8 ± 11.6EW/PBO^b^ (*n* = 100)EW/EOW^b^ (*n* = 101)EW/EW^b^ (*n* = 99)116.1 ± 61.7119.6 ± 61.7130.4 ± 60.1Open-label extension dataEOW (*n* = 1256)EW (*n* = 349)810.5 ± 432.6232.7 ± 218.9Data are presented as mean ± standard deviationEW/PBO indicates an initial period of EW treatment followed by PBO treatment; EW/EOW indicates an initial period of EW treatment followed by EOW treatment; EW/EW indicates an initial period of EW treatment followed by continued EW treatment*EOW* every-other-week dosing of adalimumab, *EW* every-week dosing of adalimumab, *HS* hidradenitis suppurativa, *PBO* placebo^a^Phase II, double-blind, placebo-controlled phase^b^Period B pooled 24-week, double-blind, placebo-controlled phase

Safety {#Sec11}
------

### Dermatologic Conditions {#Sec12}

During the phase II trial in patients with HS, AE frequency was higher with adalimumab than with placebo but similar with adalimumab EW and EOW dosing (Table [4](#Tab4){ref-type="table"}). The rates of AEs leading to discontinuation, serious AEs (SAEs), and infections were also similar between the EOW and EW groups; serious infections included one event with EOW dosing and two events with EW dosing. There were no deaths or cases of tuberculosis or opportunistic infection. There was one report of vocal cord neoplasm in the adalimumab EW group. There were two cases of new-onset/worsening psoriasis in the placebo group compared with none in the adalimumab groups. The incidence rate of injection-site reactions was higher in the EW group than in the EOW group; however, one patient in the EW group reported 8 of 11 events.Table 4Summary of adverse events in placebo-controlled analysis populations from studies of adalimumab for adults with hidradenitis suppurativaEvents (E/100 PY)Phase II, 16-week placebo-controlled studyPhase III pooled 24-week placebo-controlled period B^a^PBO (*n* = 51)\
PY 14.5EOW (*n* = 52)\
PY 16.2EW (*n* = 51)\
PY 15.0EW/PBO (*n* = 100)\
PY 31.8EW/EOW (*n* = 101)\
PY 33.1EW/EW (*n* = 99)\
PY 35.4Any AE105 (723.1)126 (783.6)124 (827.2)188 (591.2)163 (492.4)167 (471.8)Serious AE2 (13.8)3 (18.5)4 (26.7)2 (6.3)7 (21.1)5 (14.1)Any AE leading to discontinuation02 (12.4)2 (13.3)2 (6.3)2 (6.0)2 (5.6)Death00001 (3.0)0AEs of special interest Infections36 (247.9)32 (199.0)30 (200.1)55 (173.0)46 (139.0)45 (127.1)  Opportunistic infections^b^000000  Serious infections01 (6.2)2 (13.3)001 (2.8) Tuberculosis (active or latent)000000 Injection-site reactions1 (6.9)1 (6.2)11 (73.4)1 (3.1)1 (3.0)1 (2.8) Lupus-like syndrome0001 (3.1)00 Lymphoma000000 Malignancy^c^001 (6.7)000 NMSC00001 (3.0)0 Worsening/new onset psoriasis2 (13.8)001 (3.1)1 (3.0)3 (8.5) CHF00001 (3.0)0*AE* adverse event, *CHF* congestive heart failure, *E* events, *EOW* every-other-week dosing of adalimumab, *EW* every-week dosing of adalimumab, *NMSC* non-melanoma skin cancer, *PBO* placebo, *PY* patient-year^a^Period B double-blind, placebo-controlled phase. EW/PBO indicates an initial period of EW treatment followed by PBO treatment; EW/EOW indicates an initial period of EW treatment followed by EOW treatment; EW/EW indicates an initial period of EW treatment followed by continued EW treatment^b^Excluding oral candidiasis and tuberculosis^c^Excluding lymphoma and NMSC in the phase II study and lymphoma, NMSC, melanoma, leukemia, and hepatosplenic T-cell lymphoma in the phase III pooled data

In the phase III pooled data in patients with HS, rates of any AE during period B with adalimumab EOW and EW and placebo were similar (Table [4](#Tab4){ref-type="table"}). SAEs occurred more frequently with adalimumab EOW and EW than with placebo, whereas AEs leading to discontinuation occurred at similar rates across the three groups. Rates of infections in the EOW and EW groups were similar. No cases of opportunistic infection or tuberculosis and one event of non-melanoma skin cancer in the EOW dosing group were reported. There were three cases of new-onset/worsening psoriasis in the EW group compared with one each in the EOW and placebo groups. The incidence rate of injection site reactions was similar in the three groups.

In the phase II psoriasis study, the overall incidence of AEs and SAEs was higher in the EW group than in the EOW or placebo groups (Table [5](#Tab5){ref-type="table"}). Few AEs leading to discontinuation occurred in the EOW (two events) and EW (three events) groups. The rate of infections was higher in the adalimumab EW group than in the EOW group. The incidence rate of worsening/new-onset psoriasis was highest in the placebo group, and the rate of injection-site reactions was highest in the EW group; other AEs of interest occurred at low, similar rates between the groups.Table 5Summary of adverse events in studies of adalimumab for adults with psoriasisEvents (E/100 PY)Phase II, 12-week placebo-controlled studyOpen-label extension studyPBO (*n* = 52)\
PY 11.9EOW (*n* = 45)\
PY 10.2EW (*n* = 50)\
PY 11.1EOW (*n* = 1256)\
PY 2787.2EW (*n* = 349)\
PY 222.4Any AE84 (705.9)62 (607.8)110 (991.0)6623 (237.6)517 (232.5)Serious AE01 (9.8)3 (27.0)181 (6.5)17 (7.6)Any AE leading to discontinuation1 (8.4)2 (19.6)3 (27.0)80 (2.9)22 (9.9)Death0004 (0.1)1 (0.4)AEs of special interest Infections8 (67.2)8 (78.4)14 (126.1)2029 (72.8)144 (64.8)  Opportunistic infections^a^0006 (0.2)1 (0.4)  Serious infection^b^001 (9.0)33 (1.2)2 (0.9) Tuberculosis (active or latent)0005 (0.2)0 Injection-site reaction13 (109.2)8 (78.4)20 (180.2)174 (6.2)3 (1.3) Lupus-like syndrome00000 Lymphoma00000 Malignancy^c^001 (9.0)14 (0.5)3 (1.3) NMSC01 (9.8)019 (0.7)1 (0.4) Worsening/new onset psoriasis4 (33.6)01 (9.0)43 (1.5)8 (3.6) CHF0005 (0.2)3 (1.3)*AE* adverse event, *CHF* congestive heart failure, *E* events, *EOW* every-other-week dosing of adalimumab, *EW* every-week dosing of adalimumab, *NMSC* non-melanoma skin cancer, *PBO* placebo, *PY* patient-year^a^Excluding oral candidiasis and tuberculosis^b^Excluding tuberculosis in the placebo-controlled study, but including tuberculosis in the open-label study^c^Excluding lymphoma and NMSC in the placebo-controlled study and excluding lymphoma, NMSC, melanoma, leukemia, and hepatosplenic T-cell lymphoma in the open-label study

During the open-label study, the rates of any AE and SAEs were similar between the EOW and EW dosing groups (Table [5](#Tab5){ref-type="table"}). The rate of discontinuation due to an AE was higher with adalimumab EW than with adalimumab EOW. Because of the much larger exposures in the EOW group (2787.2 PY vs. 222.4 PY for EW), comparisons of other AEs of interest should be made with caution; however, the overall safety profile was similar in the EOW and EW groups.

### Non-Dermatologic Conditions {#Sec13}

In placebo-controlled Crohn's disease studies, rates of any AE, SAEs, AEs leading to discontinuation, infections, serious infections, and other AEs of interest were similar between the EOW and EW groups (Table [6](#Tab6){ref-type="table"}). In the placebo-controlled rheumatoid arthritis study, rates of any AE and SAEs were also similar between EOW and EW groups; AEs leading to discontinuation occurred more often in the EOW group than in the EW group. In the rheumatoid arthritis studies, infections and serious infections occurred at similar rates with EOW and EW dosing. Other AEs of interest also occurred at similar rates in the EOW and EW groups.Table 6Summary of adverse events in placebo-controlled studies of adalimumab for adults with Crohn's disease or rheumatoid arthritisEvents (E/100 PY)Crohn's diseaseRheumatoid arthritisPBO (*n* = 279)\
PY 101.6EOW (*n* = 279)\
PY 156.6EW (*n* = 275)\
PY 162.3PBO (*n* = 110)\
PY 37.4EOW (*n* = 113)\
PY 48.4EW (*n* = 103)\
PY 47.7Any AE1002 (986.2)1187 (758.0)1235 (760.9)944 (2524.1)1238 (2557.9)1087 (2278.8)Serious AE49 (48.2)30 (19.2)32 (19.7)26 (69.5)18 (37.2)22 (46.1)AE leading to discontinuation37 (36.4)26 (16.6)19 (11.7)3 (8.0)10 (20.7)5 (10.5)AE leading to death0003 (8.0)2 (4.1)1 (2.1)AEs of special interest Infection166 (163.4)226 (144.3)219 (134.9)64 (171.1)103 (212.8)99 (207.5)  Opportunistic infection^a^001 (0.6)2 (5.3)00  Serious infection10 (9.8)7 (4.5)7 (4.3)02 (4.1)2 (4.2) Tuberculosis000000 Injection-site reaction21 (20.7)62 (39.6)49 (30.2)11 (29.4)45 (93.0)67 (140.5) Lupus-like syndrome000000 Lymphoma000000 Malignancy^b^1 (1.0)0001 (2.1)1 (2.1) NMSC0001 (2.7)1 (2.1)0 Worsening/new-onset psoriasis04 (2.6)7 (4.3)01 (2.1)1 (2.1) CHF0002 (5.3)00*AE* adverse event, *CHF* congestive heart failure, *E* events, *EOW* every-other-week dosing of adalimumab, *EW* every-week dosing of adalimumab, *NMSC* non-melanoma skin cancer, *PBO* placebo, *PY* patient-year^a^Excluding oral candidiasis and tuberculosis^b^Excluding lymphoma, NMSC, melanoma, leukemia, and hepatosplenic T-cell lymphoma

In the open-label portions of the Crohn's disease and ulcerative colitis studies, the incidence rates of overall AEs, SAEs, and infections were higher in the EW groups than in the EOW groups (Table [7](#Tab7){ref-type="table"}). However, there was no consistent trend for higher incidence rates in the EW dosing groups for other AEs of interest, including the rate of injection-site reactions, which was similar in the EW and EOW groups. In these studies, patients escalated to EW dosing for sustained non-response to treatment or recurrent disease flare.Table 7Summary of adverse events in open-label studies of adalimumab for adults with Crohn's disease and ulcerative colitisEvents (E/100 PY)Crohn's diseaseUlcerative colitisEOW (*n* = 660)\
PY 1259.9EW (*n* = 638)\
PY 962.7EOW (*n* = 460)\
PY 1332.6EW (*n* = 440)\
PY 719.8Any AE5730 (454.8)5118 (531.6)2925 (219.5)2248 (312.3)Serious AE332 (26.4)333 (34.6)182 (13.7)149 (20.7)AE leading to discontinuation170 (13.5)137 (14.2)96 (7.2)84 (11.7)AE leading to death2 (0.2)01 (\< 0.1)1 (0.1)AEs of special interest Infection1312 (104.1)1060 (110.1)674 (50.6)505 (70.2)  Opportunistic infection^a^3 (0.2)4 (0.4)1 (\< 0.1)2 (0.3)  Serious infection77 (6.1)55 (5.7)44 (3.3)24 (3.3) Tuberculosis2 (0.2)1 (0.1)1 (\< 0.1)3 (0.4) Lupus-like syndrome3 (0.2)3 (0.3)01 (0.1) Injection-site reactions111 (8.8)41 (4.3)79 (5.9)39 (5.4) Lymphoma2 (0.2)02 (0.2)1 (0.1) Malignancy^b^13 (1.0)4 (0.4)8 (0.6)2 (0.3) NMSC13 (1.0)7 (0.7)2 (0.2)3 (0.4) Worsening/new-onset psoriasis23 (1.8)14 (1.5)10 (0.8)5 (0.7) CHF1 (\< 0.1)02 (0.2)1 (0.1)*AE* adverse event, *CHF* congestive heart failure, *E* events, *EOW* every-other-week dosing of adalimumab, *EW* every-week dosing of adalimumab, *NMSC* non-melanoma skin cancer, *PY* patient-year^a^Excluding oral candidiasis and tuberculosis^b^Excluding lymphoma, NMSC, melanoma, leukemia, and hepatosplenic T-cell lymphoma

Discussion {#Sec14}
==========

Adalimumab has a well-established safety profile across multiple indications based on more than 57,000 PY of exposure in clinical trials and postmarketing data \[[@CR28]--[@CR32]\]. The current analysis adds to the safety profile of adalimumab and demonstrates that, in adult patients with HS or psoriasis, the overall safety of 40-mg EOW and EW dosing regimens was comparable and consistent with the expected safety profile of adalimumab. The rates of AEs in the adalimumab EW and EOW dosing groups were similar in the studies for dermatologic indications, except the phase II psoriasis study, in which the overall rates of AEs and SAEs were higher in the EW group than in the EOW group. However, it should be noted that the PY of exposure in the psoriasis open-label extension were limited and were greater in the EOW group than in the EW group. There were few SAEs in the 12-week double-blind treatment period (three or fewer events in any treatment group); consequently, the observation of higher rates of AEs in the EW group may have been a chance finding. No new safety risks were identified with adalimumab EW dosing in the HS and psoriasis clinical development programs.

In the placebo-controlled studies of adalimumab for non-dermatologic indications, including Crohn's disease and rheumatoid arthritis, overall AE rates were similar for EW and EOW dosing. In the open-label Crohn's disease and ulcerative colitis studies, the patients who received EW dosing had escalated their dose due to sustained non-response to treatment or recurrent disease flares, which likely contributed to a higher rate of overall AEs and SAEs, particularly gastrointestinal-related events and other events that may be associated with worse underlying inflammatory bowel disease \[[@CR20], [@CR21], [@CR23]--[@CR26]\].

In addition, the majority of patients in the Crohn's disease, ulcerative colitis, and rheumatoid arthritis studies were receiving concomitant therapies, such as corticosteroids or other immunosuppressant therapies, which also may have confounded the results \[[@CR20]--[@CR26]\]. Nevertheless, there was no clear or consistent trend between dosing frequency and the rates of other AEs of interest for adalimumab in the non-dermatologic indication studies.

The product labeling for adalimumab recommends 40-mg EW dosing for patients with HS and 40-mg EOW dosing for patients with moderate to severe plaque psoriasis after the initial loading dose(s). The European Medicines Agency approved an amendment to the adalimumab psoriasis dosing in 2015 based on additional data \[[@CR11]\]. Specifically, "Beyond 16 weeks, patients with inadequate response may benefit from an increase in dosing frequency to 40 mg every week" \[[@CR10]\]. In patients with an inadequate response after the increased dosing frequency, the benefit-to-risk ratio should be reconsidered; in patients subsequently achieving an adequate response, the dosage may be reduced to 40 mg EOW. Based on the findings from this analysis, no new safety concerns were identified with adalimumab EW dosing compared with EOW dosing.

Overall, across all the studies examined, there was no clear trend of specific AEs occurring at a greater frequency with EW dosing versus EOW dosing. However, limitations of the analysis include a short study duration for placebo-controlled portions of the studies and small numbers of patients or imbalances in PY of exposure in some analysis groups. Patients with HS received adalimumab 40 mg EW for 12 weeks before entering period B of the phase III studies, possibly resulting in some selection bias for patients who were already tolerating adalimumab EW dosing to continue into period B. However, in the phase II, 16-week HS study in which patients had no prior adalimumab treatment, the overall safety of double-blind treatment with adalimumab was similar for patients receiving EW or EOW dosing \[[@CR12]\]. In addition, because dose escalation in some studies was initiated in response to inadequate disease control, patients whose dose was escalated may represent a different patient population than patients who did not undergo dose escalation; worsening underlying disease could have affected the rates of AEs. Furthermore, because of inherent differences among patients with different diseases, as well as disparities in concomitant medications and other factors, comparisons of AE rates across indications should be made with caution. Finally, because safety was not a primary outcome of the examined studies, no statistical tests of significance were performed on the safety data.

Conclusion {#Sec15}
==========

In this analysis of available safety data from EW and EOW dosing in patients with HS or psoriasis, the overall safety of adalimumab EW and EOW dosing regimens was comparable and consistent with the expected AE profile of adalimumab. The safety of EW adalimumab dosing in patients with dermatologic conditions is supported by data from studies comparing EW and EOW dosing of adalimumab for non-dermatologic indications, including Crohn's disease, ulcerative colitis, and rheumatoid arthritis.

Medical writing assistance was provided by Maria Hovenden, PhD, Richard Edwards, PhD, and Janet Matsuura, PhD, of Complete Publication Solutions, LLC, and was supported by AbbVie.

AbbVie funded the studies, contributed to their design, and was involved in the collection, analysis, and interpretation of the data and in the writing, review, and approval of the publication.

Conflict of interest {#FPar2}
====================

Caitriona Ryan has acted as an advisor and/or speaker for AbbVie, Aqua, Dermira, Dr. Reddy's, Janssen, Leo, Lilly, Medimetriks, Novartis, Regeneron-Sanofi, UCB, and Xenoport. Jeffrey M. Sobell has received honoraria and/or research funding from Amgen, AbbVie, Janssen, Celgene, Novartis, Lilly, Lycera, and Merck. Craig L. Leonardi has received funding from AbbVie, Actavis, Amgen, Celgene, Coherus, Dermira, Eli Lilly, Galderma, Janssen, Leo, Merck, Novartis, Pfizer, Sandoz, Stiefel, UCB, and Wyeth. Charles W. Lynde has received funding from AbbVie, Amgen, Boehringer, Celgene, Coherus, Dermira, Eli Lilly, Galderma, Innovaderm, Janssen, Leo Pharma, Merck, MSD, MedImmune, Novartis, Pfizer, Regeneron, and Xoma and reimbursement of traveling, accommodation, and hospitality expenses from AbbVie, Amgen, Boehringer, Celgene, Eli Lilly, Janssen, Leo Pharma, Merck, MSD, Novartis, Pfizer, and Valeant. Wendell C. Valdecantos and Barbara A. Hendrickson are employees of AbbVie, Inc. and may own AbbVie stock and/or stock options. Mahinda Karunaratne was an employee of AbbVie, Inc. at the time of this research and may own AbbVie stock and/or stock options.

Ethical standards {#FPar3}
=================

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent {#FPar4}
================

Informed consent was obtained from all participants in the individual studies included in these analyses.
